MedTrace Logo

Effects of NSK-SD (Nattokinase) on Blood Pressure

NCT02886507 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2016-09-01

No results posted yet for this study

Summary

This is a randomized double-blinded placebo-controlled study to evaluate the effects of NSK-SD consumption in subjects with Stage I hypertension.

The study population will be randomized into two groups, where both groups will receive dietary and lifestyle recommendations to help reduce hypertension. One group will receive placebo and the other group NSK-SD for 8 weeks.

The endpoint will be the change in systolic and diastolic blood pressure after 8 weeks of treatment in the two subject groups.

Conditions

Interventions

DIETARY_SUPPLEMENT

NSK-SD (nattokinase)

Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.

DIETARY_SUPPLEMENT

Placebo

The placebo capsules contain microcrystalline cellulose.

Sponsors & Collaborators

  • JBSL-USA Incorporated

    collaborator INDUSTRY

  • Natural Immune Systems Inc

    lead OTHER

Principal Investigators

  • Gitte S Jensen, PhD · NIS Labs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-06-30
Completion
2014-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02886507 on ClinicalTrials.gov